U.S. Precision Medicine Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global U.S. Precision Medicine Market, By Technology

7.1. U.S. Precision Medicine Market Revenue and Volume, by Technology, 2024-2034

7.1.1. Bioinformatics

7.1.1.1. Market Revenue and Volume Forecast (2021-2034)

7.1.2. Big Data Analytics

7.1.2.1. Market Revenue and Volume Forecast (2021-2034)

7.1.3. Drug Discovery

7.1.3.1. Market Revenue and Volume Forecast (2021-2034)

7.1.4. Gene Sequencing

7.1.4.1. Market Revenue and Volume Forecast (2021-2034)

7.1.5. Companion Diagnostics

7.1.6.1. Market Revenue and Volume Forecast (2021-2034)

7.1.6. Others

7.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 8. Global U.S. Precision Medicine Market, By Application

8.1. U.S. Precision Medicine Market Revenue and Volume, by Application, 2024-2034

8.1.1. CNS

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Immunology

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Oncology

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Respiratory

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global U.S. Precision Medicine Market, By End-Use

9.1. U.S. Precision Medicine Market Revenue and Volume, by End-Use, 2024-2034

9.1.1. Diagnostic Companies

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Pharmaceutical Companies

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Healthcare IT companies

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

9.1.4. Others

9.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global U.S. Precision Medicine Market, By Sequencing Technology

10.1. U.S. Precision Medicine Market Revenue and Volume, by Sequencing Technology, 2024-2034

10.1.1. Sequencing by Synthesis

10.1.1.1. Market Revenue and Volume Forecast (2021-2034)

10.1.2. Ion Semiconductor Sequencing

10.1.2.1. Market Revenue and Volume Forecast (2021-2034)

10.1.3. Sequencing by Ligation

10.1.3.1. Market Revenue and Volume Forecast (2021-2034)

10.1.4. Pyrosequencing

10.1.4.1. Market Revenue and Volume Forecast (2021-2034)

10.1.5. Single Molecule Real Time Sequencing

10.1.5.1. Market Revenue and Volume Forecast (2021-2034)

10.1.6. Chain Termination Sequencing

10.1.6.1. Market Revenue and Volume Forecast (2021-2034)

10.1.7. Nanopore Sequencing

10.1.7.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 11. Global U.S. Precision Medicine Market, By Product

11.1. U.S. Precision Medicine Market Revenue and Volume, by Product, 2024-2034

11.1.1. Consumables

11.1.1.1. Market Revenue and Volume Forecast (2021-2034)

11.1.2. Instruments

11.1.2.1. Market Revenue and Volume Forecast (2021-2034)

11.1.3. Services

11.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 12. Global U.S. Precision Medicine Market, By Route of Administration

12.1. U.S. Precision Medicine Market Revenue and Volume, by Route of Administration, 2024-2034

12.1.1. Oral

12.1.1.1. Market Revenue and Volume Forecast (2021-2034)

12.1.2. Injectable

12.1.2.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 13. Global U.S. Precision Medicine Market, By Drugs

13.1. U.S. Precision Medicine Market Revenue and Volume, by Drugs, 2024-2034

13.1.1. Alectinib

13.1.1.1. Market Revenue and Volume Forecast (2021-2034)

13.1.2. Osimertinib

13.1.2.1. Market Revenue and Volume Forecast (2021-2034)

13.1.3. Mepolizumab

13.1.3.1. Market Revenue and Volume Forecast (2021-2034)

13.1.4. Aripiprazole Lauroxil

13.1.4.1. Market Revenue and Volume Forecast (2021-2034)

13.1.5. Others

13.1.5.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 14. Global U.S. Precision Medicine Market, Regional Estimates and Trend Forecast

14.1. U.S.

14.1.1. Market Revenue and Volume Forecast, by Technology (2021-2034)

14.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)

14.1.3. Market Revenue and Volume Forecast, by End-Use (2021-2034)

14.1.4. Market Revenue and Volume Forecast, by Sequencing Technology (2021-2034)

14.1.5. Market Revenue and Volume Forecast, by Product (2021-2034)

14.1.6. Market Revenue and Volume Forecast, by Drugs (2021-2034)

14.1.7. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)

Chapter 15. Company Profiles

15.1. Biocrates Life Sciences

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Quest Diagnostics

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. NanoString Technologies

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Pfizer

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. AbbVie Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. AstraZeneca

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Johnson & Johnson Services, Inc

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Thermo Fisher Scientific, Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Illumina, Inc.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. ARIEL Precision Medicine, Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms